Therapy for poor-risk patients with small-cell lung cancer using bolus ifosfamide and oral etoposide.

2.50
Hdl Handle:
http://hdl.handle.net/10541/107632
Title:
Therapy for poor-risk patients with small-cell lung cancer using bolus ifosfamide and oral etoposide.
Authors:
Anderson, Heather; Lind, Michael J; Thatcher, Nick; Swindell, Ric; Woodcock, A A; Carroll, K B
Abstract:
A total of 47 poor-risk small-cell lung cancer patients (elderly, poor performance status, recent myocardial infarction, or extensive-stage disease with biochemical abnormalities) were treated with a regimen of bolus ifosfamide at 1.5 g/m2 with equidose mesna as a 30-min infusion, followed by 100 mg oral etoposide daily for 8 days. Therapy was repeated every 3 weeks. The overall response rate was 60% (75% for limited-stage and 48% for extensive-stage disease), and the overall median survival was 7 months. Patients' performance status significantly improved with therapy (P less than 0.0001). Despite the poor-risk factors, the Manchester prognostic score was applied and verified. The median survival was 8 months for patients with a good prognosis, 6 months for those with an intermediate prognosis and 2.5 months for poor-prognosis patients (P = 0.0002). Therapy was well tolerated. The median WHO grade of haematological toxicity was 2 (range, 0-4). Only 10/226 (4%) courses were delayed due to leukopenia. Blood transfusions followed 18/226 (8%) courses. Intravenous antibiotics were given following 15/226 (7%) courses. No patient required platelet support. Poor-risk patients who have a good or intermediate Manchester prognostic score may benefit from this low-toxicity regimen.
Affiliation:
CRC Department Medical Oncology, Christie Hospital, Manchester.
Citation:
Therapy for poor-risk patients with small-cell lung cancer using bolus ifosfamide and oral etoposide. 1990, 26 (1):71-4 Cancer Chemother Pharmacol
Journal:
Cancer Chemotherapy and Pharmacology
Issue Date:
1990
URI:
http://hdl.handle.net/10541/107632
PubMed ID:
2157555
Type:
Article
Language:
en
ISSN:
0344-5704
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorAnderson, Heatheren
dc.contributor.authorLind, Michael Jen
dc.contributor.authorThatcher, Nicken
dc.contributor.authorSwindell, Ricen
dc.contributor.authorWoodcock, A Aen
dc.contributor.authorCarroll, K Ben
dc.date.accessioned2010-07-14T15:54:14Z-
dc.date.available2010-07-14T15:54:14Z-
dc.date.issued1990-
dc.identifier.citationTherapy for poor-risk patients with small-cell lung cancer using bolus ifosfamide and oral etoposide. 1990, 26 (1):71-4 Cancer Chemother Pharmacolen
dc.identifier.issn0344-5704-
dc.identifier.pmid2157555-
dc.identifier.urihttp://hdl.handle.net/10541/107632-
dc.description.abstractA total of 47 poor-risk small-cell lung cancer patients (elderly, poor performance status, recent myocardial infarction, or extensive-stage disease with biochemical abnormalities) were treated with a regimen of bolus ifosfamide at 1.5 g/m2 with equidose mesna as a 30-min infusion, followed by 100 mg oral etoposide daily for 8 days. Therapy was repeated every 3 weeks. The overall response rate was 60% (75% for limited-stage and 48% for extensive-stage disease), and the overall median survival was 7 months. Patients' performance status significantly improved with therapy (P less than 0.0001). Despite the poor-risk factors, the Manchester prognostic score was applied and verified. The median survival was 8 months for patients with a good prognosis, 6 months for those with an intermediate prognosis and 2.5 months for poor-prognosis patients (P = 0.0002). Therapy was well tolerated. The median WHO grade of haematological toxicity was 2 (range, 0-4). Only 10/226 (4%) courses were delayed due to leukopenia. Blood transfusions followed 18/226 (8%) courses. Intravenous antibiotics were given following 15/226 (7%) courses. No patient required platelet support. Poor-risk patients who have a good or intermediate Manchester prognostic score may benefit from this low-toxicity regimen.en
dc.language.isoenen
dc.subjectLung Canceren
dc.subjectCancer Stagingen
dc.subject.meshAged-
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols-
dc.subject.meshCarcinoma, Small Cell-
dc.subject.meshEtoposide-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshIfosfamide-
dc.subject.meshLung Neoplasms-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshNeoplasm Staging-
dc.subject.meshPrognosis-
dc.subject.meshRisk Factors-
dc.titleTherapy for poor-risk patients with small-cell lung cancer using bolus ifosfamide and oral etoposide.en
dc.typeArticleen
dc.contributor.departmentCRC Department Medical Oncology, Christie Hospital, Manchester.en
dc.identifier.journalCancer Chemotherapy and Pharmacologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.